This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study To Investigate The Effect Of Erythromycin On The Pharmacokinetics Of PH-797804

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 30, 2012
Last updated: August 16, 2012
Last verified: August 2012
The purpose of this study is to investigate the effect of co-administration with erythromycin on the time course of PH-797804 concentration in the blood following dosing by oral immediate release tablet formulation.

Condition Intervention Phase
Healthy Drug: PH-797804 Drug: PH-797804 + erythromycin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Randomised, Open Label, Two Sequence, Two Treatment, Two Way Crossover Study to Estimate the Steady-state Effect of Erythromycin on the Single Dose Pharmacokinetics of Ph-797804 in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Maximum Observed Plasma Concentration (Cmax) [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose ]
  • Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose ]
  • Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose ]
  • Plasma Decay Half-Life (t1/2) [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose ]
  • Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] [ Time Frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144,168,192,216,240 hours post-dose ]

Enrollment: 12
Study Start Date: June 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PH-797804 6 mg
Subjects will receive a single 6 mg dose in the fed state
Drug: PH-797804
Tablet, 6mg, single
Experimental: PH-797804 6 mg + erythromycin 800 mg
Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
Drug: PH-797804 + erythromycin
PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple


Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male subjects and/or healthy female subjects of non-child bearing potential between the ages of 21 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lbs).

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 21 drinks/week for males.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01589614

Pfizer Investigational Site
Singapore, Singapore, 188770
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT01589614     History of Changes
Other Study ID Numbers: A6631036
Study First Received: April 30, 2012
Last Updated: August 16, 2012

Additional relevant MeSH terms:
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017